Alexion Pharmaceuticals on Thursday reached a $21 million civil settlement with the Securities and Exchange Commission to resolve charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act concerning bribes made by subsidiaries to foreign government officials in numerous countries.
